Expressions of MIF and CTGF and their relationship with prognosis of esophageal carcinoma

庞慧; 解瑞玲; 尚可; 范菲菲; 贾永旭; 李醒亚

您当前的位置：

首页 >

文章列表页 >

Expressions of MIF and CTGF and their relationship with prognosis of esophageal carcinoma

更新时间：2026-01-09

- Expressions of MIF and CTGF and their relationship with prognosis of esophageal carcinoma
- Journal of Army Medical University Vol. 33, Issue 4, Pages: 372-375(2011)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC： R341;R446.6;R735.1
- Published：2011
- 稿件说明：
移动端阅览
庞慧,解瑞玲,尚可,范菲菲,贾永旭,李醒亚.巨噬细胞移动抑制因子和结缔组织生长因子在食管癌中的表达及其与预后的关系[J].陆军军医大学学报(原第三军医大学学报),2011,33(04):372-375.

　Pang Hui,Xie Ruiling,Shang Ke,Fan Feifei,Jia Yongxu,Li Xingya.Expressions of MIF and CTGF and their relationship with prognosis of esophageal carcinoma[J].J Amry Med Univ (J Third Mil Med Univ),2011,33(04):372-375.
庞慧,解瑞玲,尚可,范菲菲,贾永旭,李醒亚.巨噬细胞移动抑制因子和结缔组织生长因子在食管癌中的表达及其与预后的关系[J].陆军军医大学学报(原第三军医大学学报),2011,33(04):372-375. DOI：

　Pang Hui,Xie Ruiling,Shang Ke,Fan Feifei,Jia Yongxu,Li Xingya.Expressions of MIF and CTGF and their relationship with prognosis of esophageal carcinoma[J].J Amry Med Univ (J Third Mil Med Univ),2011,33(04):372-375. DOI：

摘要

目的研究食管癌组织中巨噬细胞移动抑制因子（macrophage migration inhibitory factor

MIF）和结缔组织生长因子(connective tissue growth factor

CTGF )的表达情况及其对预后的影响。方法应用免疫组织化学染色法检测MIF和CTGF在84例食管癌组织中的表达水平，应用Cox回归模型和Kaplan-Meier生存曲线分析其与患者预后的关系。结果本组病例3年生存率为59.5% （50/84）。MIF和CTGF的表达与肿瘤浸润深度（P=0.006，P=0.011）和肿瘤的临床分期（P=0.023

P=0.006）密切相关。单因素生存分析表明

MIF和CTGF低表达组较高表达组均有生存优势，差异均有统计学意义(P0.05)。Cox模型多因素分析表明，食管癌组织中CTGF表达水平、临床分期和肿瘤分化程度是影响食管癌患者生存的独立预后因素(P0.05)。结论食管癌组织中CTGF高表达、肿瘤低分化和临床分期较晚与患者预后不良显著相关。

Abstract

Objective To investigate the expression and prognostic value of macrophage migration inhibitory factor (MIF) and connective tissue growth factor (CTGF) in esophageal carcinoma. Methods The expression of MIF and CTGF were detected by SP immunohistochemistry in 84 specimens of pathologically identified esophageal carcinoma tissue collected by Department of Thoracic Surgery of our hospital from Jan. 1 2004 to Jun. 30 2006. The clinical data including TNM stages and differentiation were respectively analyzed. They were all followed up till Jun 30 2010. The relationship of the expressions with prognosis of patients was evaluated by Cox regression model and Kaplan-Meier survival curve analysis. Results The three-year overall survival rate of the patients was 59.5% (50/84). The expression of MIF and CTGF were significantly associated with the depth of tumor infiltration (P=0.006

P=0.011) and TNM stage (P=0.023

P=0.006). Univariate survival analysis suggested that three-year survival rate of the patients with high CTGF and MIF expressions was poorer than those with lower expressions. Cox multivariate analysis indicated that CTGF expression

TNM staging and differential degree were the independent prognostic factors affecting survival rate of patients (P0.05). Conclusion High CTGF expression is associated with a poor prognosis in esophageal cancer. CTGF is a useful prognostic marker for esophageal carcinoma.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

A novel estrogen receptor expression stratification (low/moderate/high) based on Chinese population provides more accurate prognosis prediction for HR⁺/HER2^- early breast cancer patients

Immunosuppressive microenvironment of TGIF1-overexpressing gastric cancers and its clinical significance

Impact of molecular heterogeneity of NPM1 mutations on prognosis of acute myeloid leukemia: a clinical report of 86 cases

Association of 5-factor modified frailty index and controlling nutritional status score with overall survival in patients with unresectable hepatocellular carcinoma undergoing interventional therapy

Construction and validation of prediction model for cervical cancer recurrence based on systemic inflammation response index and clinicopathological parameters

Related Author

WANG Chengfang

ZHOU Yuqin

ZHANG Yanling

QI Xiaowei

ZHANG Yi

TONG Huyun

CHEN Xu

ZHANG Wenjie

Related Institution

Department of Breast and Thyroid Surgery， First Affiliated Hospital， Army Medical University （Third Military Medical University）

Department of Gastroenterology， Chongqing Hechuan District People’s Hospital

School of Medicine， Chongqing University

Chongqing Key Laboratory of Precision Prevention and Treatment for Digestive System Tumors， Department of Gastroenterology， Army Medical Center of PLA/Daping Hospital of Third Military Medical University

Department of Hematology, the First Hospital of Lanzhou University

⁰